Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Phase 3

Completed

• Conditions: Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome
• Interventions: Drug: Glasdegib; Drug: Azacitidine

• Registration Number: NCT04842604
• Lead Sponsor: Pfizer

Brief Summary

An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-08
• Study First Submitted QC: 2021-04-08
• Study First Posted: 2021-04-13
• Study Start: 2021-05-17
• Primary Completion: 2022-12-02
• Study Completion: 2022-12-02
• Status Verified: 2023-11
• Results First Submitted: 2023-11-27
• Results First Submitted QC: 2023-11-27
• Last Update Submitted: 2023-11-27
• Results First Posted: 2023-12-18
• Last Update Posted: 2023-12-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Any participant who continues to demonstrate clinical benefit (as determined by the Principal Investigator) from study treatment with azacitidine with or without glasdegib in this Study or from Study B1371012.
• Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion Criteria

• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Female participants who are pregnant or breastfeeding (if continuing to receive study intervention);
• Participant has been withdrawn from Study B1371019 and Study B1371012 for any reason (including INT cohort participants required to end study treatment)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Participants from B1371019 and B1371012	Glasdegib	Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed. The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study. Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study.
Participants from B1371019 and B1371012	Azacitidine	Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed. The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study. Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment Emergent Adverse Event (AE) and Treatment Related AE	From initiation of study treatment to study completed from 17-May-2021 to 02-Dec-2022 (approximately 565 days)	AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if the event occurred during the on-treatment period (regardless of if it was seen prior to the start of treatment). An AE was considered treatment related as assigned by the investigator.
Number of Participants With Treatment Emergent Serious Adverse Events (SAE) and Treatment Related SAEs	From initiation of study treatment to study completed from 17-May-2021 to 02-Dec-2022 (approximately 565 days)	A SAE was defined as any untoward medical occurrence that, at any dose that resulted in death; was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or other medical events as per investigator's judgement. A SAE was considered treatment emergent if the event occurred during the on-treatment period (regardless of if it was seen prior to the start of treatment). A SAE was considered treatment related as assigned by the investigator.

Trial Locations

Locations (18)

Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU; 🇦🇹 Salzburg, Austria

Uniklinikum Salzburg, Landeskrankenhaus Salzburg; 🇦🇹 Salzburg, Austria

Health Sciences Centre; 🇨🇦 Winnipeg, Manitoba, Canada

CancerCare Manitoba; 🇨🇦 Winnipeg, Manitoba, Canada

Ustavni lekarna; 🇨🇿 Ostrava - Poruba, Czechia

Klinika hematoonkologie; 🇨🇿 Ostrava-Poruba, Czechia

CHU de Nantes; 🇫🇷 Nantes cedex 1, France

CHU de Nantes Hotel Dieu; 🇫🇷 Nantes cedex, France

Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek; 🇭🇺 Debrecen, Hungary

Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika; 🇭🇺 Debrecen, Hungary

Scroll for more (8 remaining)